Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts

Journal of Rheumatology

Volumn 32, Issue 5, 2005, Pages 787-795

  Yoshida, Minoru ^a   Kanno, Yosuke ^a   Ishisaki, Akira ^a   Tokuda, Haruhiko ^b   Hirade, Kouseki ^a   Nakajima, Keiichi ^a   Katagiri, Yoshihiro ^a   Shimizu, Katsuji ^a   Kozawa, Osamu ^a,c  

^a Department of Pharmacology ^*

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Inflammation; Interleukin 6; Methotrexate; Osteoblast; Rheumatoid arthritis

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; METHOTREXATE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE C ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

3T3 CELLS; ANIMALS; ANTIRHEUMATIC AGENTS; CARCINOGENS; CELLS, CULTURED; DINOPROST; DINOPROSTONE; DRUG INTERACTIONS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-6; METHOTREXATE; MICE; OSTEOBLASTS; PROSTAGLANDIN D2; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18744387718     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-11.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. 2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis. Z Rheumatol 1984;43:89-96.
4. Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Invest Drugs 2003;4:572-7.
5. Nijweid PJ, Burger EH, Feyen JHM. Cells of bone: proliferation, differentiation and hormonal regulation. Physiol Rev 1986; 66:855-86.
6. Vergne P, Liagre B, Bertin P, et al. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol 1998;25:433-40.
7. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology Oxford 2002;41:1367-74.
8. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998;78 Suppl 3:1-7.
9. Williams HJ, Wilkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
10. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
11. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 1985;103:489-96.
12. 5α. J Rheumatol 1987;14:9-11.
13. Segal R, Mozes E, Yaron M, Tartakovsky B. The effect of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370-7.
14. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
15. Mello SBV, Barros DM, Silva ASF, Laurindo IMM, Novaes GS. Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology Oxford 2000;39:533-6.
16. Hagel-Bradway S, Dziak R. Regulation of bone cell metabolism. J Oral Pathol Med 1989;18:344-51.
17. Aggarwal A, Misra R. Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 2003;23:134-7.
18. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappa B ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
19. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990;4:2860-7.
20. van Snick JV. Interleukin-6: An overview. Ann Rev Immunol 1995;8:253-97.
21. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3297-303.
22. Roodman GD. Interleukin-6; an osteotropic factor? J Bone Miner Res 1992;7:475-8.
23. Kozawa O, Suzuki A, Kaida T, Tokuda H, Uematsu T. Tumor necrosis factor-α autoregulates interleukin-6 synthesis via activation of protein kinase C. J Biol Chem 1997;272:25099-104.
24. Miwa M, Kozawa O, Tokuda H, Uematsu T. Mitogen-activated protein (MAP) kinases are involved in interleukin-1 (IL-1)-induced IL-6 synthesis in osteoblasts: modulation not of p38 MAP kinase, but of p42/p44 MAP kinase by IL-1-activated protein kinase C. Endocrinology 1999;140:5120-5.
25. 2+ mobilization in osteoblasts: regulation by protein kinase C. Prostaglandins Leukot Essent Fatty Acids 1999;61:189-94.
26. 2: cross-talk regulation by protein kinase C. Bone 1998;22:355-60.
27. 2α- induced interleukin-6 synthesis in osteoblasts. Cell Signal 1999;11:325-30.
28. Sudo H, Kodama AH, Amagi Y, Yamamoto S, Kasi S. In vivo differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983;96:191-8.
29. 2 in osteoblast-like cells. Exp Cell Res 1992;198:130-4.
30. Okahashi N, Nakamura I, Jimi E, Koide M, Suda T, Nishihara T. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res 1997;12:1116-23.
31. Ishiyama M, Miyazono Y, Sakamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenetic indicator for NADH as well as cell viability. Talanta 1997; 44:1299-305.
32. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O. Interleukin (IL)-17 enhances tumor necrosis factor-α-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem 2004;91:1053-61.
33. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002;30 Suppl 65:3-9.
34. 2α stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells. Am J Physiol 1997;272:E208-11.
35. Carter CA. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 2000;1:163-83.
36. Ewa MP. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4:S81-S90.
37. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
38. Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:377-80.
39. 1 in osteoblasts. J Clin Invest 1994;93:2490-6.
40. 2α-induced vascular endothelial growth factor synthesis in osteoblasts. Enhancement of MAPK activity. J Biol Chem 2003;278:18930-7.
41. Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology Oxford 2003;42 Suppl 2:3-10.
42. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002;8:147-59.
43. Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology Oxford 2002;41:1232-9.
44. Demis E, Roux C, Breban M, Dougados M. Infliximab in spondylarthropathy - influence on bone density. Clin Exp Rheumatol 2002;20:S185-6.
45. Smith WL, Garavito RM, De Witt DL. Prostaglandin endoperoxide synthase (cyclooxygenase)-1 and -2. J Biol Chem 1996; 271:33157-60.
46. Nowak D, Lewandowicz J, Dbkowska B, Marczak J. Combination of methotrexate and prednisone decreases circulating concentrations of interleukin 1 beta and interleukin 6 in patients with rheumatoid arthritis. Poor correlation of cytokine suppression with clinical improvement. Int J Immunopathol Pharmacol 1999;12:13-21.
47. 2α. Prostaglandins Leukot Essent Fatty Acids 1992;45:267-74.
48. 2-stimulated heat shock protein 27 induction in osteoblasts. Cell Signal 2001;13:535-41.
49. 2-stimulated heat shock protein 27 induction in osteoblasts. Prostaglandins Leukot Essent Fatty Acids 2004;71:351-62.
50. Obrig TG, Culp WJ, McKeehan WL, Hardesty B. The mechanism by which cycloheximide and related glutarimide ant biotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 1971;246:174-81.
51. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 1986;29:832-5.